Abstract
Objective: To estimate the budgetary impact of adopting selinexor (XPOVIO; Karyopharm Therapeutics, Inc.) for the treatment of adult patients with pen......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
